Targeting Platelets for the Treatment of Cancer
AbstractThe majority of cancer-associated mortality results from the ability of tumour cells to metastasise leading to multifunctional organ failure and death. Disseminated tumour cells in the blood circulation are faced with major challenges such as rheological shear stresses and cell-mediated cytotoxicity mediated by natural killer cells. Nevertheless, circulating tumour cells with metastatic ability appear equipped to exploit host cells to aid their survival. Despite the long interest in targeting tumour-associated host cells such as platelets for cancer treatment, the clinical benefit of this strategy is still under question. In this review, we provide a summary of the latest mechanistic and clinical evidence to evaluate the validity of targeting platelets in cancer. View Full-Text
Share & Cite This Article
Elaskalani, O.; Berndt, M.C.; Falasca, M.; Metharom, P. Targeting Platelets for the Treatment of Cancer. Cancers 2017, 9, 94.
Elaskalani O, Berndt MC, Falasca M, Metharom P. Targeting Platelets for the Treatment of Cancer. Cancers. 2017; 9(7):94.Chicago/Turabian Style
Elaskalani, Omar; Berndt, Michael C.; Falasca, Marco; Metharom, Pat. 2017. "Targeting Platelets for the Treatment of Cancer." Cancers 9, no. 7: 94.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.